Sasha Jovanovic
4 min read
Biotech stocks live and die on access to capital, so the Federal Reserve’s signal that interest rates may pause for now gives this high risk corner of the market some breathing room. Cheaper money can make it easier to fund drug pipelines and clinical trials, which matters if you are hunting for the next breakthrough. This article highlights three financially grounded biotech stocks that could potentially benefit from this environment.
The three biotech stocks in focus below are just a small sample, and the wider screen surfaced 87 more businesses with similarly compelling stories that are not covered here. To go straight to the full Biotech Stocks screener and identify which ideas best fit your own criteria, analyze the Biotech Stocks screener.
Arrowhead Pharmaceuticals (ARWR)
Overview: Arrowhead Pharmaceuticals develops RNA interference medicines targeting hard to treat cardiometabolic and rare diseases, led by late stage RNAi drug candidates.
Operations: Arrowhead reports US$669 million in revenue from nanotechnology related activity, all generated in the United States.
Market Cap: US$8.2 billion
Arrowhead Pharmaceuticals matters in this Biotech Stocks screen because its RNAi platform is already pushing late stage programs toward conditions with high unmet need, where clinical success can rapidly reshape expectations for future value.
“Although plozasiran’s triglyceride and pancreatitis risk reductions support use in high risk severe hypertriglyceridemia, the decision to buy an expensive Priority Review Voucher and pursue STAR program acceleration pulls forward SHTG launch costs into 2026 and 2027. This could weigh on Arrowhead Pharmaceuticals’ earnings before incremental revenue has time to build.”
What happens to Arrowhead’s long term appeal depends heavily on how one unseen pressure ultimately feeds through to margins and cash needs.
That margin pressure question is exactly what the full narrative for Arrowhead Pharmaceuticals tackles, laying out how Arrowhead Pharmaceuticals’ pipeline, cash runway and partnership options could reshape the risk reward balance.
Supernus Pharmaceuticals (SUPN)
Overview: Supernus Pharmaceuticals develops and sells prescription treatments for central nervous system conditions, with ADHD, epilepsy and Parkinson’s therapies supported by a growing CNS pipeline.
Operations: Supernus Pharmaceuticals generates about US$830 million in pharmaceutical revenue, all from CNS focused medicines sold in the United States.
Market Cap: US$2.4 billion
